Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver tumor and
remains a fatal malignancy in the majority of patients. Approximately 20%–30% of patients …

Gallbladder cancer (GBC) is the most common cancer of the biliary tract, characterized by a
very poor prognosis when diagnosed at advanced stages owing to its aggressive behaviour …

Background S-1 has shown promising efficacy with a mild toxicity profile in patients with
advanced biliary tract cancer. The aim of this study was to evaluate whether adjuvant S-1 …

Background Despite improvements in multidisciplinary management, patients with biliary
tract cancer have a poor outcome. Only 20% of patients are eligible for surgical resection …

Malignant liver tumours include a wide range of primary and secondary tumours. Although
surgery remains the mainstay of curative treatment, modern therapies integrate a variety of …

Biliary tract cancers, including intrahepatic, perihilar, and distal cholangiocarcinoma as well
as gallbladder cancer, are low-incidence malignancies in most high-income countries, but …

Background Although some retrospective studies have suggested the value of adjuvant
therapy, no recommended standard exists in bile duct cancer. The aim of this study was to …

PURPOSE The BILCAP study described a modest benefit for capecitabine as adjuvant
therapy for curatively resected biliary tract cancer (BTC), and capecitabine has become the …

Cholangiocarcinoma (CCA) is a heterogeneous group of neoplasms of the bile ducts and
represents the second most common hepatic cancer after hepatocellular carcinoma; it is sub …

This paper presents the first version of clinical practice guidelines for intrahepatic
cholangiocarcinoma (ICC) established by the Liver Cancer Study Group of Japan. These …